NCT05106140

Brief Summary

The RELEARN trial is a a prospective longitudinal cohort study sampled by convenience. Stroke survivors and healthy control individuals will be recruited to analyze motor learning in the upper extremity and its neural basis in early stroke recovery.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
4mo left

Started Sep 2021

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress94%
Sep 2021Sep 2026

First Submitted

Initial submission to the registry

May 31, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

September 20, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 3, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

November 3, 2021

Status Verified

July 1, 2021

Enrollment Period

5 years

First QC Date

May 31, 2021

Last Update Submit

November 2, 2021

Conditions

Keywords

RehabilitationNeuroimagingMotor LearningEarly Stroke RecoveryNeuroplasticityLimb Dominance

Outcome Measures

Primary Outcomes (3)

  • Changes in Path Deviations

    Initial path deviations (IPDs) will be measured during each robotic task movement and used to measure learning in each session.

    Control participant: baseline only; Stroke participant: week 1 and week 26

  • Peak Lateral Deviations

    Peak lateral deviations (PLDs) will be measured during each robotic task movement and used to measure learning in each session.

    Control participant: baseline only; Stroke participant: week 1

  • Peak Lateral Deviations

    Peak lateral deviations (PLDs) will be measured during each robotic task movement and used to measure learning in each session.

    Stroke participant: week 26

Secondary Outcomes (13)

  • Robotic Assessment

    Control participant: baseline; Stroke participant: week 1, week 6, week 12, and week 26

  • Motor Learning

    Control participant: baseline only; Stroke participant: week 1 and week 26

  • Arm Reflexes

    Stroke participant only: week 1, week 6, week 12, and week 26

  • Modified Ashworth Scale (MAS)

    Stroke participant only: week 1, week 6, week 12, and week 26

  • Strength

    Stroke participant only: week 1, week 6, week 12, and week 26

  • +8 more secondary outcomes

Study Arms (2)

Stroke Participants

This group will include stroke survivors from the Calgary Stroke Program who are over 18 years of age.

Other: Magnetic Resonance Imaging (MRI)Device: Kinarm Robotic Exoskeleton AssessmentOther: Clinical Assessment

Control Participants

This group will include healthy individuals from the community who are matched for age and sex to stroke participants.

Device: Kinarm Robotic Exoskeleton AssessmentOther: Clinical Assessment

Interventions

A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.

Stroke Participants

The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements. The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours.

Control ParticipantsStroke Participants

The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.

Control ParticipantsStroke Participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are 7±6 days post-stroke from the Calgary Stroke Program will be included in this study, as well as healthy control volunteers from the community.

You may qualify if:

  • First time, unilateral ischemic stroke in middle cerebral artery territory, motor and/or sensory tracts and confirmed by clinical examination (including neuroimaging)
  • ±6 days post-stroke
  • Upper limb impairment
  • \>18 years old
  • Fugl-Meyer upper extremity score between 30 and 57
  • Vision better than 20/50 (corrected)
  • Able to follow 3-step task commands
  • \>18 years old
  • Good health

You may not qualify if:

  • History of:
  • past undiagnosed stroke (evident on neuroimaging),
  • neglect (screened with Behavioral Inattention Test),
  • apraxia, or
  • upper extremity orthopedic or muscular issues
  • Secondary neurologic injury or disease (e.g., Parkinson's)
  • Contraindication to MRI
  • Medical or neuropsychiatric conditions that would interfere with study outcomes, or where participation presents a risk to the subject
  • Enrollment in an interventional trial that supplements standard therapy
  • Significant upper limb neurologic or orthopedic conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Carewest Dr. Vernon Fanning Centre

Calgary, Alberta, T2E 6V7, Canada

RECRUITING

University of Calgary - Kinesiology Building

Calgary, Alberta, T2N 1N4, Canada

RECRUITING

Foothills Hospital - Main Building

Calgary, Alberta, T2N2T9, Canada

RECRUITING

University of Calgary - Teaching Research and Wellness (TRW) Building

Calgary, Alberta, T2N2T9, Canada

RECRUITING

MeSH Terms

Conditions

Stroke

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Tyler Cluff, PhD

    University of Calgary, Calgary, Alberta, Canada

    PRINCIPAL INVESTIGATOR
  • Sean Dukelow, MD PhD FRCPC

    University of Calgary, Calgary, Alberta, Canada

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rachel Stone, BA

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2021

First Posted

November 3, 2021

Study Start

September 20, 2021

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

November 3, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations